

Bromocriptine

1

A Case of Hyperprolactinemia Treated by Vaginal Bromocriptine Administration

Y. S. Nam, W. S. Lee, C. Park, T. K. Yoon and K. Y. Cha

Department of Obstetrics and Gynecology, College of Medicine,
Pocheon CHA University, Pocheon, Korea

= Abstract =

The clinical spectrum of prolactin – related infertility includes galactorrhea, amenorrhea, oligomenorrhea, luteal insufficiency, and possibly subtle follicular dysfunction, all of which occur as a result of hyperprolactinemia. These features are commonly encountered in women with primary disorders of prolactin metabolism, namely, prolactin – secreting pituitary tumors, or hyperprolactinemias. Idiopathic or functional hyperprolactinemia and the empty sella syndrome are also included in this group. Bromocriptine, a dopamine agonist, has an established therapeutic role in the treatment of hyperprolactinemia, with or without a prolactin – secreting adenoma. However, the oral route of administration is associated in about 50 – 70% of patients with adverse side effects, most commonly nausea, vomiting, headache, and dizziness. Most of these reactions are mild and tend to occur in the early stages of therapy. However, as many as 10% of patients experience severe side effects requiring

discontinuation of therapy. We have experienced a case of hyperprolactinemia treated by vaginal bromocriptine administration which showed severe side effects via oral route. So we report this case with a brief review of literatures.

Key Words : Hyperprolactinemia, Vaginal bromocriptine

가 .

Bromocriptine

parlodel SRO, parlodel LAR, pergolide mesylate, cabergoline, CV205 – 502, bromocriptine

Bromocriptine , 4 (fourth

ventricle) (chemoreceptor

trigger zone) dopamine . 가 ,

Bromocriptine 4.2%

가
가
Bromocriptine
bromocriptine

30
2 - 3
가
가
165 cm, 48 kg, 120 / 80 mmHg, 36.5°C,
80 /

가
LH : 11.3 mIU/ml, FSH : 25.7 mIU/ml, prolactin :
348.8 ng/ml, TSH : 1.73 μ U/ml, DHEA - S : 67.2 μ g/dl
(sella turcica)

Parlodel
Parlodel
2
가
가 62.8 ng/ml
Parlodel
Parlodel
44.2 ng/ml
Parlodel
52.1 ng/ml

(agonist) bromocriptine

28%

5 90%

3 - 7 8 - 12

Bromocriptine estrogen 가 가

(galactorrhea)

(2.5 - 5mg /) bromocriptine (10mg /)

70%

(microadenoma) 가 10%가 1

가 1 6 bromocriptine

Bromocriptine 가

bromocriptine bromocriptine

bromocriptine 1

bromocriptine (lactotroph) 가

2 bromocriptine

DNA , ,

3 bromocriptine 가

15

6 5 가 50%가

4 가 4

가 가 5

가 24 - 6

Bromocriptine 가 80 - 90% 7

가 가

8

가

bromocriptine 가

bromocriptine

bromocriptine 6 - 12

bromocriptine 10

bromocriptine 10

bromocriptine

가

2.5mg 가

Bromocriptine 가

10 - 15% 가

(vasospasm), (nasal congestion),

(orthostatic hypotension) 가

bromocriptine 1.25mg 7 - 10 2.5mg 2

1 - 2

7.5mg 1% Bromocriptine

phenothiazine bromocriptine

bromocriptine 가

가
bromocriptine
가
bromocriptine
가
¹⁸⁻²⁰ Bromocriptine
가
¹⁹ bromocriptine
bromocriptine
²¹
가 가
Bromocriptine 가
30 Bromocriptine 2.5mg
¹⁸
가
2.5mg
가
bromocriptine
Bromocriptine
bromocriptine
가
bromocriptine
가
Bromocriptine
가
bromocriptine
가
200pg/mL
bromocriptine 가 가
Bromocriptine
가
²²
1
bromocriptine
²³

1. Thorner MO, Schran HF, Evans WS, Rogol AD, Morris JL, MacLeod RM : A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women : a study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine. *J Clin Endocrinol Metab* 1980 ; 50 : 1026 –33.
2. Pellegrini I, Rasolonjanahary R, Gunz G : Resistance to bromocriptine in prolactinomas. *J Clin Endocrinol Metab* 1989 ; 69 : 500 –9.
3. MacLeod RM, Lehmeyer JE : Pituitary tumor growth and function by ergot alkaloids. *Cancer Res* 1973 ; 33 : 849 –55.
4. Bonneville JF, Poulignot D, Cattin F, Couturier M, Mollet E, Dietemann JL : Computed tomographic demonstration of the effects of bromocriptine on pituitary microadenoma size. *Radiology* 1982 ; 143 : 451 –5.
5. Demura R, Kubo O, Demura H, Shizume K, Kitamura K : Changes in computed tomographic findings in microprolactinomas before and after bromocriptine. *Acta Endocrinol* 1985 ; 110 : 308 –12.
6. Thorner MO, Martin WH, Rogol AD : Rapid regression of pituitary prolactinomas during bromocriptine treatment. *J Clin Endocrinol Metab* 1980 ; 51 : 438 –45.
7. Molitch ME, Elton RL, Blackwell RE : Bromocriptine as primary therapy for prolactin –secreting macroadenomas : results of a prospective multicenter study. *J Clin Endocrinol Metab* 1985 ; 60 : 698 –705.
8. Fahlbusch R, Buchfelder M, Schrell U : Short – term preoperative treatment of macroprolactinomas by dopamine agonists. *J Neurosurg* 1987 ; 67 : 807 –15.
9. Warfield A, Finkel DM, Schatz NJ, Savino PJ, Snyder PJ : Bromocriptine treatment of prolactin –secreting pituitary adenomas may restore pituitary function. *Ann Intern Med* 1984 ; 101 :

783 – 5.

10. Dalzell GW, Atkinson AB, Carson DJ, Sheridan B : Normal growth and pubertal development during bromocriptine treatment for a prolactin – secreting pituitary macroadenoma. Clin Endocrinol 1987 ; 26 : 169 – 72.
11. Landolt AM, Osterwalder V : Perivascular fibrosis in prolactinomas : is it increased by bromocriptine? J Clin Endocrinol Metab 1984 ; 58 : 1179 – 83.
12. Esiri MM, Bevan JS, Burke CW, Adams CBT : Effect of bromocriptine treatment on the fibrous tissue content of prolactin – secreting and nonfunctioning macroadenomas of the pituitary gland. J Clin Endocrinol Metab 1986 ; 63 : 383 – 8.
13. Bevan JS, Adams CBT, Burke CW : Factors in the outcome of transsphenoidal surgery for prolactinoma and nonfunctioning pituitary tumor including preoperative bromocriptine therapy. Clin Endocrinol 1987 ; 26 : 541 – 56.
14. Johnston DG, Prescott RWG, Kendall – Taylor P : Hyperprolactinemia : long – term effects of bromocriptine. Am J Med 1983 ; 75 : 868 – 74.
15. Ho KY, Smythe GA, Compton PJ, Lazarus L : Long – term bromocriptine therapy may restore the inhibitory control of prolactin release in some patients with pathological hyperprolactinemia. Aust N Z J Med 1985 ; 15 : 213 – 9.
16. Thorner MO, Perryman RL, Rogol AD : Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J Clin Endocrinol Metab 1981 ; 53 : 480 – 3.
17. Turner TH, Cookson JC, Wass JAH, Drury PL, Price PA, Besser GM : Psychotic reactions during treatment of pituitary tumors with dopamine agonists. Br Med J 1984 ; 289 : 1101 – 3.
18. Vermesh M, Fossum GT, Kletzky OA : Vaginal bromocriptine : pharmacology and effect on serum prolactin in normal women. Obstet Gynecol 1988 ; 72 : 693 – 8.
19. Jasonni VM, Raffelli R, de March A, Frank G, Flamigni C : Vaginal bromocriptine in hyperprolactinemic patients and puerperal women. Acta Obstet Gynecol Scand 1991 ; 70 :

493 - 5.

20. Ginsburg J, Hardiman P, Thomas M : Vaginal bromocriptine : clinical and biochemical effects. *Gynecol Endocrinol* 1992 ; 6 : 119 –26.
21. Katz E, Schran HF, Adashi EY : Successful treatment of a prolactin – producing pituitary macroadenoma with intravaginal bromocriptine mesylate : a novel approach to intolerance of oral therapy. *Obstet Gynecol* 1989 ; 73 : 517 –20.
22. Cuellar FG : Bromocriptine mesylate(Parlodel) in the management of amenorrhea / galactorrhea associated with hyperprolactinemia. *Obstet Gynecol* 1980 ; 5 : 278 –84.
23. Schran HF, Bhuta SI, Schwarz HJ, Thorner MO : The pharmacokinetics of bromocriptine in man. In : Goldstein M, Calne D, Leiberman A, Thorner MO, editor. *Ergot compounds and brain function : Neuroendocrine and neuropsychiatric aspects*. New York : Raven Press ; 1980. p.125 –39.